Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome

Neurochem Res. 2022 Oct;47(10):3076-3092. doi: 10.1007/s11064-022-03659-0. Epub 2022 Jun 29.

Abstract

Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer's disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS. Progressive loss of cholinergic neurons is one of the hallmarks of AD present in DS and in the Ts65Dn model. In this study, we quantify the number of cholinergic neurons in control and Ts65Dn mice, observing a general reduction in their number with age but in particular, a greater loss in old Ts65Dn mice. Increased expression of the m1 muscarinic receptor in the hippocampus counteracts this loss. Cholinergic neurons in the Ts65Dn mice display overexpression of the early expression gene c-fos and an increase in the expression of β-galactosidase, a marker of senescence. A possible mechanism for senescence induction could be phosphorylation of the transcription factor FOXO1 and its retention in the cytoplasm, which we are able to confirm in the Ts65Dn model. In our study, using Ts65Dn mice, we observe increased cholinergic activity, which induces a process of early senescence that culminates in the loss of these neurons.

Keywords: Cholinergic neurons; Down syndrome; Muscarinic receptors; Premature aging; Senescence; Ts65Dn; c-fos.

MeSH terms

  • Alzheimer Disease* / metabolism
  • Animals
  • Cholinergic Agents
  • Disease Models, Animal
  • Down Syndrome*
  • Mice
  • Mice, Transgenic

Substances

  • Cholinergic Agents